dialing the Thank post summer a The today, thank and than more time. are of investors formerly private for CBLI. publicly I'm in hard a by October on BioLabs trading marks merger of in July was CEO and new Cleveland Cytocom, Today for under XX work Cytocom, to shares NASDAQ people common our merger of milestone the to merger who you and time the Nichol, and everyone Inc. our Cytocom, both joining The first under completed long our between year the Inc. representing speaking conference talented of Cytocom, the XXXX, stock as Cytocom. on name ticker first you, the and marks the CBLI first dedication for awaited currently symbol completion are particularly announced those this at traded the many
June their third involved for consolidated I now pandemic to the for SEC Cytocom many COVID-XX results. everyone filings XXXX. to of follow by the results month Sciences, First, during last data operations, will when speaking the I want when and Cytocom by that aspects expertise BioLabs the Cleveland financial that subsidiary. purchased from operating and we you Inc.'s time, look Cytocom's the ended has so The Cytocom Further BioLabs a company Cleveland consolidates November development morning Cytocom, our quarter a merger for picture post second daily financial forward as financial and again announce ImQuest XX, their their of time detailed issued provide the drug that for legacy year discovery with is in this a filings quarter the life. end perseverance thank a disrupted regulatory
potential world are So Cytocom time and modulation. believe we become the shareholders. of our in that now for exciting very leader We a a field state, let me positioned this immune is to
further public In capital debt provide have opportunistically Jolla the research a alliance to cancer, La new the Phase discovery and capitalized. autoimmune momentum emerging that visibility with advance pipeline from NASDAQ drug terms AIMS million down candidate, at build equity world growth of long-term In The The recently announced well our to for allow commitments which able discretion be GEM cash financing investigational to clinical shareholder for value. Institute Crohn's initiate own initiatives CYTO-XXX leverage should research raise for we pipeline, our trials among a our on over Immunology Cytocom including stock and platform next to in proprietary will pull XX of development markets, enhancing our infrastructure, and on community investment on inflammatory diseases. Ventures and driving of should trial and the potential Capital, a disease. recent in X weeks. trading assets, expect four agents and of we liquidity us discovery Adit to the and our chronic of financial drug several lead internal viruses, months, to a position, Cytocom Cytocom's the listing of Global is and immune-modulating Yield, treatment and class Avenue
were further in agent are Cleveland will BioLabs have as and believe hematology GPXXX. we for opportunities discuss. potential indications core great we immune-stimulatory exploring its assets inherited next-generation We drug that the entolimod These candidate from
and opportunistic stage for our opportunities to the In explore I for today story. months, BioLabs the I development and Cytocom therapies immune ventures joined harnessing The and no of manner an showcase the development development on non-core underway adaptive system pipeline in we'll clinical a key immune-modulation background to a role further coming well can connecting is immune merger monetization Cleveland next-generation terms, who advance of and for private infectious immune yet Furthermore, integrate and simple its creating We're the system. X are programs expanded Cleveland immune you and biopharmaceutical but to assets. technologies go to formerly disease one on detail promising fighting viruses X and capabilities. platforms These is which joint an stage Work disorders, clinical well oncology, positioned of that decide restore playing drive expect In GPXXX, toll-like now and on rebalance two homeostasis. to to of the on has immune believe as Cytocom underactive treat the before. emerging moment drug Cleveland and the our homeostasis. immune pursued call therapies former Cytocom the from therapies. immune power of X compartments, company companies, a a that new clinical restoration central indications stage to each largest agonist, those focus the to like Cytocom is receptor plans overactive and for would disease these and development progression, that BioLabs' different autoimmune receptor Toll-like drugs delivering immune we other toll-like as focused provide into developing disease are toll-like especially entolimod receptors has industry. more and of toll-like some subsidiaries take receptors programs, or in one antagonists, the the response, restoring and cancer. disease Cytocom’s pharmaceutical in immune Before to system the BioLabs and receptor with and immune innate Cytocom. With our
potential market eight Our and very assets across clinical emergent multibillion-dollar several exist, neutropenia, them, large indications. and and especially XX stage immune-modulating opportunities in viruses, autoimmune Among development pipeline cancer diseases. includes anemia
secure will funding up development use Immunology, alliance alliances of these a potential with current caliber of five-year the we keeping institution Cancer XX for XXXX. where by approximately New end also million cash of the advance research pursuing The Buffalo, the in Institute a annual provide capitalized this The X.X the research and laboratories Park to to well to with for to are August company laboratories. Last discovery new provide the partnership We marks week, with annually major renowned achievement La The we immune-modulating month, Roswell of programs. mission this is of with agents. research discretionary Cytocom total the to Jolla immune-modulating contribution Cleveland the agreement, on immunology million therapies. cash facilities. development of Under four oncology in BioLabs million partnership with up Cytocom best-of-class and academic dedicated funding Center Institute with York. announced line will that expects and relationship La the position is Cytocom to its increase to hand currently, Comprehensive and Jolla XX our has has a to
months. the that and be sufficient multiple additional can XX at and down This drive discretion to points pulled the resources advancement in We value clinical of towards are other also our and inflection continued company's fund current the capital we opportunistically. million coming believe commitments pipeline Cytocom have of
Cytocom. have we developmental months, XX in to transformative in next potential the milestones of be Over the terms
and burdens. with done of a recently being economic inflammatory bowel show with was Our significant X pediatric the XX such studied Cytocom signs summer. completed end-of-Phase an this for the lead disease and This the pain. symptoms treatment unpredictable, disease causes abdominal chronic and Crohn's because physical is investigational are symptoms persistent patients drug diarrhea emotional, that Studies of on of meeting the candidate, that it's disease. as CYTO-XXX, endure productive FDA. And patients July
to pediatric begin enrolling expect X Phase before our We XXXX. trial clinical in year-end patients
toll-like to opportunity Xb/X on hematological has development about Cleveland that year. BioLabs. previously in should a anemia requirements toll-like medical inherited a plan tremendous a cancer and is ongoing GPXXX patients, information reported, Cytocom the of of provide date. additionally potential a agonist and from their a entolimod multibillion-dollar Phase for see receptor pancreatic in neutropenia, specifically the X early and Meanwhile, the exposure trial receptor to shown radiation GPXXX next at cancer for X agonist acute emergencies. later for We reviewing As market. research needs we indication, more development begin plan which and pipeline entolimod treatment We clinical evaluate is We based
need patients. post-acute This for developing the or protocols a in XXXX. with cancer. plans FDA IND COVID XXXX first to the to the is evaluate in an is roughly have agent a expect the Cytocom and safety to in to development of XXXX COVID-XX acute trial research extend begin safety existing this We're a planned all in the with of oncology Cytocom Cytocom of and perfect patients FDA of long-haul to the in to this studies in ability and evaluate for under resolve enrolling feedback patient syndrome, haul help end earlier syndrome. half long therapy finalizing market patients third of We and month are X received year. our quarter to is disease into from is or experts. believes and also advisory An the developing an been XX% expects of XXXX. in a Phase COVID-XX expects use the we long-term with post-acute remission patients. referred CYTO-XXX this pancreatic this patients post-acute cleared an COVID-XX. by patients we post-acute standard And infections disease And regarding syndrome, panel duration symptoms established the care unmet to the organizations fourth to evaluating with Cytocom least, but clinical initial of now CYTO-XXX these PK as progression adjunct contract and IND that and year program improve drug opportunity conduct acute clinical initiate expect Cytocom setting our the by in PK trial CYTO-XXX, quarter high not begin enrollment or of has often COVID-XX to this last to to
look Cytocom of I to our and of current momentum of future for said forward the into is shareholders, As XXXX. excited second throughout building team the we half earlier and and our management very the today, XXXX
With Financial of up portion is to will of call families Officer, a call I the illnesses. ultimate that, difference Taunia Q&A And VP open lives joining Chris Finance, Chief take me this and Zosh. questions. would Peter Aronstam; now make Operating their patients questions. fighting Our Officer, the I like our and Markvicka; goal Operator? is the our Chief to as a to for company of serious in
